Roumell Investor Day, November 5, 2015


Interview with John Hass, CEO of Rosetta Stone Inc., followed by Q&A


Interview with Jay Allison, CEO, and Roland Burns, CFO of Comstock Resources Inc., followed by Q&A


Interview with Evan Loh, Chief Medical Officer of Paratek Pharmaceuticals Inc., followed by Q&A


Performance Disclosures:
Please refer to the Annual Disclosure Presentations for our Opportunistic Value Composite, which has been prepared and presented in compliance with the Global Investment Performance Standards (GIPS®). Performance reflects RAM’s deep value investment strategy. Returns are reported net of all management fees and applicable trading costs and include the reinvestment of all income. Investors should understand that past performance is not indicative of future performance. Investors should not assume that investments made on their behalf by RAM will be profitable and may, in fact, result in a loss. Ashland Partners & Co. LLP, our independent verifier, completed its examination of the firm’s performance returns for the period of 1999 (inception) through December 31, 2016.

Additional Disclosures:
The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for advisory clients and the reader should not assume that investments in the securities identified and discussed were or will be profitable.
A list of all purchases and sales made over the last 12 months is available upon request.

2 Wisconsin Circle, Suite 640 | Chevy Chase, MD 20815 | Phone: (301) 656-8500 | Fax: (301) 656-8501 | Map and Directions LinkedIn